Stopped: Due to low enrollment
A follow-up study to evaluate the safety and clinical outcomes of patients with inherited metabolic disorders (IMD) who have undergone hematopoietic stem cell transplantation (HSCT) with MGTA-456
Age range
16 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of related adverse events
Timeframe: 2 years
Incidence of serious adverse events
Timeframe: 2 years
Incidence of late hematological graft failure
Timeframe: 2 years
Incidence of chronic graft versus host disease
Timeframe: 2 years
Overall survival
Timeframe: 2 years
Event-free survival
Timeframe: 2 years
Change in cALD Neurologic Function Score over time
Timeframe: 2 years
Proportion of subjects without gadolinium enhancement on MRI over time
Timeframe: 2 years
Alpha-iduronidase blood enzyme level (nmol/hr/mg) in Hurler patients
Timeframe: 2 years
Very long chain fatty acid blood level (ug/mL) in cALD patients
Timeframe: 2 years